Hemab Therapeutics

Forecast & Rating5 analysts currently cover Hemab Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $61.20, about 46.7% upside from the current price of $41.72. Price targets are fairly clustered, pointing to relatively aligned views. For you, this means most professionals who study Hemab Therapeutics closely still see room for the stock to rise. Data as of Sep 9, 2026; for reference only and not investment advice.